Physician perspectives on de-intensifying diabetes medications

Area of Science:

• Endocrinology and Metabolic Diseases
• Clinical Practice Guidelines
• Diabetes Management

Background:

• Current diabetes care guidelines emphasize individualized glycemic targets based on patient factors.
• However, specific recommendations for de-intensifying diabetes medications in patients with stable hemoglobin A1C (HbA1C) levels are lacking.

Purpose of the Study:

• To investigate physicians' perspectives on de-intensifying diabetes medications for patients with type 2 diabetes.
• To understand physician practices and considerations when adjusting medication intensity.

Main Methods:

• A cross-sectional survey was conducted among primary care and endocrinology physicians.
• Physicians reported on their awareness, agreement, and frequency of individualizing HbA1C goals and de-intensifying medications.
• Data were collected on specific HbA1C thresholds and patient factors influencing de-intensification decisions.

Main Results:

• Most physicians (78%) were familiar with individualizing HbA1C goals, and 80% discussed stopping medications with patients.
• Significant variation existed in the HbA1C levels used to initiate de-intensification.
• Women physicians and those in practice <20 years were more likely to report de-intensifying medications.

Conclusions:

• Physicians generally accept the concepts of individualizing glycemic goals and de-intensifying diabetes treatments.
• There is considerable variability in how physicians implement these recommendations, potentially leading to missed opportunities for medication adjustment.
• Further research is needed to standardize de-intensification protocols based on individualized patient needs.